Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1993-3-5
|
| pubmed:abstractText |
An experimental intravitreal sustained-release device containing ganciclovir was used to treat 22 patients with acquired immunodeficiency syndrome-associated cytomegalovirus retinitis. Fourteen eyes were excluded (five not involved and nine with macular scarring and/or severe debility). Thirty eyes received the ganciclovir intraocular device implant and were prospectively followed up from 16 to 419 days (median, 125 days). Twenty-seven (90%) of 30 eyes showed stabilization of the retinitis. Nine (33%) of 27 eyes showed reactivation of the retinitis once the device was empty of ganciclovir; seven received a replacement device, with subsequent stabilization of the retinitis. Postoperative complications included vitreous hemorrhage (n = 1), endophthalmitis (n = 1), and progressive retinitis (n = 2). Late retinal detachment was seen in three eyes (11%) at 35 to 140 days. Survival analysis of all 30 eyes revealed the mean time to progression of retinitis to be 19 weeks (133 days). The ganciclovir intraocular device offers a promising alternative for the treatment of cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0003-9950
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
111
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
223-7
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8141855-AIDS-Related Opportunistic Infections,
pubmed-meshheading:8141855-Adult,
pubmed-meshheading:8141855-Cytomegalovirus Infections,
pubmed-meshheading:8141855-Delayed-Action Preparations,
pubmed-meshheading:8141855-Drug Implants,
pubmed-meshheading:8141855-Follow-Up Studies,
pubmed-meshheading:8141855-Ganciclovir,
pubmed-meshheading:8141855-Hospitals, University,
pubmed-meshheading:8141855-Humans,
pubmed-meshheading:8141855-Infusions, Intravenous,
pubmed-meshheading:8141855-Male,
pubmed-meshheading:8141855-Middle Aged,
pubmed-meshheading:8141855-Ophthalmoscopy,
pubmed-meshheading:8141855-Postoperative Complications,
pubmed-meshheading:8141855-Prospective Studies,
pubmed-meshheading:8141855-Recurrence,
pubmed-meshheading:8141855-Retinitis,
pubmed-meshheading:8141855-Severity of Illness Index,
pubmed-meshheading:8141855-Survival Analysis,
pubmed-meshheading:8141855-Texas,
pubmed-meshheading:8141855-Visual Acuity
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir.
|
| pubmed:affiliation |
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Case Reports,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|